High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23

Scandinavian Journal of Gastroenterology

Volumn 51, Issue 11, 2016, Pages 1332-1338

  Dahlerup, Jens Frederik ^a   Jacobsen, Bent A ^b   van der Woude, Janneke ^c   Bark, Lars Åke ^d   Thomsen, Lars L ^e   Lindgren, Stefan ^f  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e Pharmacosmos AS   (Denmark)

^f LUND UNIVERSITY   (Sweden)

Author keywords

Anaemia; FGF23; hypophosphataemia; IBD; intravenous iron; iron deficiency

Indexed keywords

FERRITIN; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; IRON; IRON ISOMALTOSIDE; PHOSPHATE; TRANSFERRIN; UNCLASSIFIED DRUG; DISACCHARIDE; FERRIC ION; FIBROBLAST GROWTH FACTOR; IRON ISOMALTOSIDE 1000;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; EYE ALLERGY; FEMALE; FEVER; HUMAN; HYPOPHOSPHATEMIA; INFLAMMATORY BOWEL DISEASE; IRON DEFICIENCY ANEMIA; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RETICULOCYTE; SINGLE DRUG DOSE; VOMITING; ANEMIA, IRON-DEFICIENCY; BLOOD; CLINICAL TRIAL; COMPLICATION; DENMARK; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; NETHERLANDS; SWEDEN; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANEMIA, IRON-DEFICIENCY; DENMARK; DISACCHARIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRIC COMPOUNDS; FERRITINS; FIBROBLAST GROWTH FACTORS; HEMOGLOBINS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NETHERLANDS; PHOSPHATES; PROSPECTIVE STUDIES; QUALITY OF LIFE; SWEDEN; YOUNG ADULT;

EID: 84975266509     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365521.2016.1196496     Document Type: Article

References (27)

1. J.Stein, F.Hartmann, A.U.Dignass. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7:599–610.
2. J.Stein, A.U.Dignass. Management of iron deficiency anemia in inflammatory bowel disease – a practical approach. Ann Gastroenterol. 2013;26:104–113.
3. J.P.Gisbert, F.Bermejo, R.Pajares,. Oral and intravenous iron treatment in inflammatory bowel disease:hematological response and quality of life improvement. Inflamm Bowel Dis. 2009;15:1485–1491.
4. F.Gomollon, J.P.Gisbert. Anemia and inflammatory bowel diseases. World J Gastroenterol. 2009;15:4659–4665.
5. C.W.Wells, S.Lewis, J.R.Barton,. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123–130.
6. C.Gasche, M.C.Lomer, I.Cavill,. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53:1190–1197.
7. A.U.Dignass, C.Gasche, D.Bettenworth,. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis. 2015;9:211–222.
8. C.Gasche, A.Berstad, R.Befrits,. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis. 2007;13:1545–1553.
9. W.Reinisch, M.Staun, R.K.Tandon,. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol. 2013;108:1877–1888.
10. W.Reinisch, I.Altorjay, F.Zsigmond,. A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease. Scand J Gastroenterol. 2015;50:1226–1233.
11. B.Wikstrom, S.Bhandari, P.Barany,. Iron isomaltoside 1000:a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011;24:589–596.
12. ®) as maintenance therapy in haemodialysis patients. Nephrol Dial Transplant. 2015;30:1577–1589.
13. P.A.Kalra, S.Bhandari, S.Saxena,. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant. 2015;31:646–655.
14. P.R.Hildebrandt, N.E.Bruun, O.W.Nielsen,. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. Transfus Altern Transfus Med. 2010;11:131–137.
15. ®) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof:a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang. 2015;109:257–266.
16. M.Wolf, T.A.Koch, D.B.Bregman. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28:1793–1803.
17. T.A.Koch, J.Myers, L.T.Goodnough. Intravenous iron therapy in patients with iron deficiency anemia:dosing considerations. Anemia. 2015. doi:10.1155/2015/763576.
18. D.Gozzard. When is high-dose intravenous iron repletion needed? Assessing new treatment options. Drug Des Devel Ther. 2011;5:51–60.
19. P.Bager, J.F.Dahlerup. The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective. J Crohns Colitis. 2010;4:427–430.
20. European Medicine Agency. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines, EMA/377372/2013; 2013.
21. A.Blazevic, J.Hunze, J.M.Boots. Severe hypophosphataemia after intravenous iron administration. Neth J Med. 2014;72:49–53.
22. B.J.Schouten, P.J.Hunt, J.H.Livesey,. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose:a prospective study. J Clin Endocrinol Metab. 2009;94:2332–2337.
23. Y.Shimizu, Y.Tada, M.Yamauchi,. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide:another form of FGF23-related hypophosphatemia. Bone. 2009;45:814–816.
24. T.Shimada, H.Hasegawa, Y.Yamazaki,. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–435.
25. T.Shimada, T.Muto, I.Urakawa,. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002;143:3179–3182.
26. E.G.Farrow, X.Yu, L.J.Summers,. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA. 2011;108:E1146–E1155.
27. D.B.Bregman, M.L.Tokars. inventors. Patent application publication. Patent number US 2014/0162974 A1, application number US 13/821,072, 12; Jun 2014.